International immunopharmacology · 2020
Subcutaneous administration of interferon beta-1a for COVID-19: A non-controlled prospective trial.
Клиническое исследованиеСтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Dastan Farzaneh, Nadji Seyed Alireza, Saffaei Ali, Marjani Majid, Moniri Afshin, Jamaati Hamidreza, Hashemian Seyed MohammadReza, Baghaei Parvaneh, Abedini Atefeh, Varahram Mohammad, Yousefian Sahar, Tabarsi Payam
Аннотация
BACKGROUND: Recently, a new coronavirus spreads rapidly throughout the countries and resulted in a worldwide epidemic. Interferons have direct antiviral and immunomodulatory effects. Antiviral effects may include inhibition of viral replication, protein synthesis, virus maturation, or virus release from infected cells. Previous studies have shown that some coronaviruses are susceptible to interferons. The aim of this study was to evaluate the therapeutic effects of IFN-β-1a administration in COVID-19.
METHODS: In this prospective non-controlled trial, 20 patients included. They received IFN-β-1a at a dose of 44 µg subcutaneously every other day up to 10 days. All patients received conventional therapy including Hydroxychloroquine, and lopinavir/ritonavir. Demographic data, clinical symptoms, virological clearance, and imaging findings recorded during the study.
RESULTS: The mean age of the patients was 58.55 ± 13.43 years. Fever resolved in all patients during first seven days. Although other symptoms decreased gradually. Virological clearance results showed a significant decrease within 10 days. Imaging studies showed significant recovery after 14-day period in all patients. The mean time of hospitalization was 16.8 ± 3.4 days. There were no deaths or significant adverse drug reactions in the 14-day period.
CONCLUSIONS: Our findings support the use of IFN-β-1a in combination with hydroxychloroquine and lopinavir/ritonavir in the management of COVID-19.
CLINICAL TRIAL REGISTRATION NUMBER: IRCT20151227025726N12.
METHODS: In this prospective non-controlled trial, 20 patients included. They received IFN-β-1a at a dose of 44 µg subcutaneously every other day up to 10 days. All patients received conventional therapy including Hydroxychloroquine, and lopinavir/ritonavir. Demographic data, clinical symptoms, virological clearance, and imaging findings recorded during the study.
RESULTS: The mean age of the patients was 58.55 ± 13.43 years. Fever resolved in all patients during first seven days. Although other symptoms decreased gradually. Virological clearance results showed a significant decrease within 10 days. Imaging studies showed significant recovery after 14-day period in all patients. The mean time of hospitalization was 16.8 ± 3.4 days. There were no deaths or significant adverse drug reactions in the 14-day period.
CONCLUSIONS: Our findings support the use of IFN-β-1a in combination with hydroxychloroquine and lopinavir/ritonavir in the management of COVID-19.
CLINICAL TRIAL REGISTRATION NUMBER: IRCT20151227025726N12.
Предметные рубрики MeSH
AdolescentAdultAgedAged, 80 and overAntiviral AgentsBetacoronavirusCOVID-19Coronavirus InfectionsDrug CombinationsDrug Therapy, CombinationFemaleHumansHydroxychloroquineInjections, SubcutaneousInterferon beta-1aLopinavirLungMaleMiddle AgedPandemicsPneumonia, ViralProspective StudiesRitonavirSARS-CoV-2Tomography, X-Ray ComputedTreatment OutcomeYoung AdultCOVID-19 Drug Treatment